Craig Eagle - 07 Jun 2023 Form 4 Insider Report for MyMD Pharmaceuticals, Inc. (TNFA)

Reporting relationship: Director
Issuer ticker: TNFA
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 18:00:21 UTC
Prior SEC filing: 16 May 2023
Next SEC filing: 13 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Craig Eagle

Key filing fact

Craig Eagle filed Form 4 for MyMD Pharmaceuticals, Inc. (TNFA) on 09 Jun 2023.

Key facts

This page summarizes Craig Eagle's Form 4 filing for MyMD Pharmaceuticals, Inc. (TNFA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 18:00.

Change

Previous filing in this sequence was filed on 16 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MYMD transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +475,000
Change %
Price: $0.000000
Shares after: 475,000
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 475,000
Exercise price: $1.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.